Management change at Boule Diagnostics U.S. subsidiary

Boule Diagnostics AB (publ) has appointed Group CFO Fredrik Alpsten as acting President of the U.S. subsidiary Clinical Diagnostic Solutions (CDS). Fredrik Alpsten succeeds Andrew Swanson. Fredrik Alpsten takes on the position on December 6, 2012.

North America is currently Boule Diagnostics largest market, where a large part of the development of reagents, calibrators and controls is conducted. The market is the single most developed market for hematology products in the world, and there are several conditions for continued stable growth for Boule Diagnostics. As the Boule Diagnostics business continues to grow and the company takes market share, the Boule Diagnostics Group deemed it the right time for a leadership change.

“Boule Diagnostics’ North American operations have developed, and are expected to continue to develop, strong. Fredrik Alpsten has insight into the Boule Diagnostics business and he has many years of experience in senior positions in both listed and private companies operating in the North American market. This means that we can continue to strengthen the cooperation between the Swedish and American business, and with an unchanged pace continue to develop CDS until a permanent CEO has been recruited”, said Ernst Westman, President and CEO Boule Diagnostics.

For further information, please contact:
Ernst Westman, President and CEO Boule Diagnostics AB, phone +46-708-60 88 63

The information in this press release is such that Boule Diagnostics AB must disclose it in accordance with the Securities Market Act and/or the Financial Instruments Trading. The information was submitted for publication at 8:30 am (CET), December 6, 2012.  

About Boule Diagnostics AB
Boule Diagnostics AB is a fast-growing diagnostics company, developing and manufacturing systems and consumables for hematology diagnostics for the public healthcare providers worldwide. The company is primarily focused on small and medium-sized hospitals, clinics and laboratories in outpatient care as well as other diagnostics companies in both human and veterinary haematology. The group is comprised of operating subsidiaries in Sweden, the US and China. Boule Diagnostics’ share is, since 2011, traded on NASDAQ OMX Nordic.


  • Subscribe to our news